Actionable news
All posts from Actionable news
Actionable news in RLYP: RELYPSA Inc,

Relypsa Announces Upcoming Veltassa® Data Presentations at National Kidney Foundation 2016 Spring Clinical Meetings

REDWOOD CITY, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (RLYP), a biopharmaceutical company, today announced that new analyses from studies of Veltassa® (patiromer) for oral suspension will be presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings, taking place April 27-May 1 in Boston.

Veltassa was approved by the U.S. Food and Drug Administration for the treatment of hyperkalemia in the United States on October 21, 2015, becoming the first medicine in more than 50 years for people with elevated serum potassium.

Data to be presented include:

  • Results from a proof of concept study (RLY5016-201) that evaluated the effect of Veltassa on potassium and phosphate in six hyperkalemia patients on hemodialysis;
  • An analysis evaluating the effect of Veltassa on urine calcium and phosphate excretion from the Phase 1 RLY5016-101 and 102 studies in healthy adults;
  • Data from a post-hoc sub-group analysis of patients with resistant hypertension in the Phase 2 AMETHYST-DN trial, which evaluated Veltassa over 52 weeks in hyperkalemia patients with chronic kidney disease (CKD) and type 2 diabetes who were taking renin angiotensin aldosterone system (RAAS) inhibitors.

Additionally, an epidemiologic research poster presentation will highlight results of a longitudinal study that evaluated racial differences in the prevalence, patterns and mortality associated with hyperkalemia among U.S. veterans.

Presenters will be available for questions at posters on Thursday, April 28, from 6:00-7:30 p.m. ET. Posters will be available for viewing over the course of the conference.

Veltassa Poster Presentations

Abstract Title: Patiromer decreases serum potassium and phosphate in patients on hemodialysis
Presenter:David A. Bushinsky, M.D., John J. Kuiper Distinguished Professor of Medicine and of Pharmacology and...